<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31786407</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>409</Volume><PubDate><Year>2020</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Plasma from some patients with amyotrophic lateral sclerosis exhibits elevated formaldehyde levels.</ArticleTitle><Pagination><StartPage>116589</StartPage><MedlinePgn>116589</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2019.116589</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(19)32353-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this study was to determine whether patients with amyotrophic lateral sclerosis (ALS) exhibit higher plasma levels of formaldehyde (FA) than controls, and to look for alterations in levels of FA precursors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied 40 heathy controls and 50 ALS patients from the Motor Neuron Disease clinic at the Royal Brisbane &amp; Women's Hospital. Plasma FA levels were quantified using a FA detection assay. Trimethylamine (TMA) and trimethylamine oxide (TMAO) in plasma were quantified by multiple reaction monitoring (MRM) mass spectrometry. Plasma levels in patients and controls were compared using Mann-Whitney U test and Spearman's correlation test was used to assess the correlation between levels of FA, TMA, TMAO and other variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The levels of plasma FA were significantly greater in ALS subjects than controls. TMA and TMAO levels were not significantly different between healthy controls and patients, but were greater in ALS subjects with elevated FA levels than those with normal levels. Of note, levels of TMA and TMAO demonstrated a significant positive correlation with plasma FA levels (spearman's correlation coefficients of TMA with FA [r&#xa0;=&#xa0;0.451, p&#xa0;=&#xa0;0.010] and TMAO [r&#xa0;=&#xa0;0.401, p&#xa0;=&#xa0;0.023]). There was no association of FA levels with disability measured with the ALS functional rating scale, with the duration of disease or with the age of the subjects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Elevated FA is found in some patients with ALS. FA is neurotoxic and could contribute to disease pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Aven</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The University of Queensland, UQ Centre for Clinical Research, Brisbane, QLD 4029, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arachchige</LastName><ForeName>Buddhika Jayakody</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Facility, UQ Centre for Clinical Research, Brisbane, QLD 4029, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Facility, UQ Centre for Clinical Research, Brisbane, QLD 4029, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Brisbane &amp; Women's Hospital, Brisbane, QLD 4029, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aylward</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wesley Medical Research, Wesley Hospital, Auchenflower, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCombe</LastName><ForeName>Pamela Ann</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>The University of Queensland, UQ Centre for Clinical Research, Brisbane, QLD 4029, Australia; Wesley Medical Research, Wesley Hospital, Auchenflower, QLD, Australia. Electronic address: Pamela.McCombe@uq.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008744">Methylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HG84L3525</RegistryNumber><NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance></Chemical><Chemical><RegistryNumber>FLD0K1SJ1A</RegistryNumber><NameOfSubstance UI="C005855">trimethyloxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>LHH7G8O305</RegistryNumber><NameOfSubstance UI="C023336">trimethylamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008744" MajorTopicYN="N">Methylamines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011793" MajorTopicYN="N" Type="Geographic">Queensland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Formaldehyde</Keyword><Keyword MajorTopicYN="N">Microbiome</Keyword><Keyword MajorTopicYN="N">Toxins</Keyword><Keyword MajorTopicYN="N">Trimethylamine</Keyword><Keyword MajorTopicYN="N">Trimethylamine N-oxide</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors report no conflict of interest. The authors alone are responsible for the content and paper writing.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31786407</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2019.116589</ArticleId><ArticleId IdType="pii">S0022-510X(19)32353-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>